GLP-1受体激动剂因其显著的体重减轻效果和糖尿病治疗效果,成为广受关注的药物。然而,尽管现有的GLP-1类药物取得了辉煌的成就,许多制药公司,包括已经在减肥药领域飞龙在天的诺和诺德与礼来,依然希望能通过新药来突破市场,开发出既方便又高效的治疗方案。礼来在作用“不尽财富滚滚来”的Zepbound之后,将下一个突破点瞄准到了小分子资产orforglipron,希望提供一种口服替代方案来治疗肥胖症和...
Source LinkGLP-1受体激动剂因其显著的体重减轻效果和糖尿病治疗效果,成为广受关注的药物。然而,尽管现有的GLP-1类药物取得了辉煌的成就,许多制药公司,包括已经在减肥药领域飞龙在天的诺和诺德与礼来,依然希望能通过新药来突破市场,开发出既方便又高效的治疗方案。礼来在作用“不尽财富滚滚来”的Zepbound之后,将下一个突破点瞄准到了小分子资产orforglipron,希望提供一种口服替代方案来治疗肥胖症和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.